One shot gene therapy could end monthly eye injections for wet AMD
NCT ID NCT06825858
First seen Jan 11, 2026 · Last updated Jun 12, 2026 · Updated 31 times
Summary
This early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged 50 to 85 who previously responded to standard anti-VEGF therapy will receive a single dose to check safety and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kanghong Investigative Site
Phoenix, Arizona, 85016, United States
-
Kanghong Investigative Site
Lemont, Illinois, 60439, United States
-
Kanghong Investigative Site
Memphis, Tennessee, 38138, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.